Synopsis

Source of validity: Scientific
Rating (out of 5): 1

Nicotinamide Adenine Dinucleotide (NAD⁺) has garnered interest in the context of Multiple Sclerosis (MS) due to its central role in cellular energy metabolism and neuroprotection. Preclinical studies, mainly in animal models and cellular systems, have shown that NAD⁺ and its precursors may help mitigate neurodegeneration and inflammation, which are key features of MS pathology. For example, research in experimental autoimmune encephalomyelitis (EAE), an animal model of MS, suggests that boosting NAD⁺ levels can reduce demyelination and improve neurological outcomes, potentially by enhancing mitochondrial function and reducing oxidative stress.

However, robust clinical evidence in humans is lacking. As of June 2024, no large-scale, peer-reviewed clinical trials have demonstrated clear efficacy or safety of NAD⁺ supplementation or related compounds (such as nicotinamide riboside or nicotinamide mononucleotide) in people with MS. The theoretical rationale is based on preclinical data, but translation into clinical practice awaits more definitive research. Thus, while the use of NAD⁺ or its precursors in MS is scientifically motivated, the current level of evidence is low, and its use as a treatment or supportive therapy for MS is not established.

More about Nicotinamide Adenine Dinucleotide
More about Multiple Sclerosis

Other ingredients used for Multiple Sclerosis

Other health conditions supported by Nicotinamide Adenine Dinucleotide

Products containing Nicotinamide Adenine Dinucleotide